HK2 and leukemia: Recent studies have found that the rate-limiting glycolysis enzyme, PKM2, is a key target for the DMAMCL-induced inhibition of cell proliferation in leukemia and glioma; however, these studies found no significant differences in PFKL or HK2 mRNA expression [11, 15].